Patient’s features | Total (n = 104) | Non-hypermethylated (n = 80) | Hypermethylated (n = 24) | P value |
---|---|---|---|---|
Sex (male/female) | 61/43 | 48/32 | 13/11 | 0.642 |
Median age, years (range) | 62 (14–86) | 63.5 (14–86) | 67 (28–86) | 0.689 |
Median WBC, ×109/L (range) | 2.7 (0.6–82.4) | 2.8 (0.6–82.4) | 2.5 (1.1–44.4) | 0.457 |
Median hemoglobin, g/L (range) | 64 (26–140) | 66 (36–140) | 56 (26–107) | 0.017 |
Median platelets, ×109/L (range) | 60 (0–1176) | 60 (0–754) | 50 (10–1176) | 0. 503 |
Median BM blasts, % (range) | 5.0 (0.0–19.0) | 5.0 (0.0–19.0) | 11.0 (0.0–18.0) | 0.006 |
WHO classifications (2018) | Â | Â | Â | 0.020 |
 MDS-SLD | 10 | 9 (11%) | 1 (4%) |  |
 MDS-RS | 7 | 6 (8%) | 1 (4%) |  |
 MDS-MLD | 32 | 29 (36%) | 3 (13%) |  |
 MDS-EB1 | 20 | 16 (20%) | 4 (17%) |  |
 MDS-EB2 | 31 | 18 (23%) | 13 (54%) |  |
 MDS with isolated del(5q) | 3 | 1 (1%) | 2 (8%) |  |
 MDS-U | 1 | 1 (1%) | 0 (0%) |  |
IPSS scores | Â | Â | Â | 0.021 |
 Low | 11 | 9 (11%) | 2 (8%) |  |
 Int-1 | 52 | 45 (56%) | 7 (29%) |  |
 Int-2 | 22 | 16 (20%) | 6 (25%) |  |
 High | 12 | 5 (6%) | 7 (29%) |  |
No data | 7 | 5 (6%) | 2 (8%) | Â |
Gene mutations | Â | Â | Â | Â |
 CEBPA (+/−) | 3/91 | 3/71 | 0/20 | > 0.999 |
 IDH1/2 (+/−) | 3/91 | 3/71 | 0/20 | > 0.999 |
 DNMT3A (+/−) | 3/91 | 3/71 | 0/20 | > 0.999 |
 U2AF1 (+/−) | 6/88 | 1/73 | 5/15 | 0.001 |
 SRSF2 (+/−) | 5/89 | 4/70 | 1/19 | > 0.999 |
 SF3B1 (+/−) | 6/98 | 4/70 | 2/18 | 0.604 |